Pfizer takes over development of hemophilia A gene therapy SB-525
Pfizer will take over development of the hemophilia A gene therapy SB-525, which the company had originally developed with Sangamo Therapeutics, as the candidate advances into late-stage clinical trials. Pfizer has begun recruitment of participants for the trial to further assess the treatment's safety and efficacy. Hemophilia News Today (1/6)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!